Halozyme Therapeutics, Inc. (HALO)

Market Cap	5.01B
Revenue (ttm)	829.25M
Net Income (ttm)	281.59M
Shares Out	127.05M
EPS (ttm)	2.10
PE Ratio	18.77
Forward PE	10.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,619
Open	38.98
Previous Close	38.97
Day's Range	38.82 - 39.70
52-Week Range	29.85 - 45.00
Beta	1.26
Analysts	Buy
Price Target	53.00 (+34.42%)
Earnings Date	May 7, 2024

About HALO

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO

Financial Performance

In 2023, HALO's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.

Analyst Forecast

According to 7 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $53.0, which is an increase of 34.42% from the latest price.

Price Target

$53.0

(34.42% upside)

Analyst Consensus: Buy